


World Journal of *Psychiatry*

World J Psychiatry 2024 February 19; 14(2): 194-333



EDITORIAL

- 194** Keep in mind sex differences when prescribing psychotropic drugs
Mazza M, De Berardis D, Marano G
- 199** Therapeutic approach to emotional reactions accompanied with thermal skin injury - from basic to epidemiological research
Krstic B, Krstic M, Selakovic D, Jovicic N, Rosic G
- 204** Climate change, ambient air pollution, and students' mental health
Wang JX, Liu XQ
- 210** Catatonia: A deep dive into its unfathomable depths
Phiri P, Delanerolle G, Hope O, Murugaiyan T, Dimba G, Rathod S, Zingela Z

FIELD OF VISION

- 215** Cognitive dissonance and mindset perturbations during crisis: "eco-socio-psycho-somatic" perspectives
Tretter F, Löffler-Stastka H

MINIREVIEWS

- 225** Automatic recognition of depression based on audio and video: A review
Han MM, Li XY, Yi XY, Zheng YS, Xia WL, Liu YF, Wang QX

ORIGINAL ARTICLE**Case Control Study**

- 234** Impaired implicit emotion regulation in patients with panic disorder: An event-related potential study on affect labeling
Wang HY, Li LZ, Chang Y, Pang XM, Zhang BW

Retrospective Cohort Study

- 245** Incidence and risk factors of depression in patients with metabolic syndrome
Zhou LN, Ma XC, Wang W

Retrospective Study

- 255** Analysis of risk factors leading to anxiety and depression in patients with prostate cancer after castration and the construction of a risk prediction model
Li RX, Li XL, Wu GJ, Lei YH, Li XS, Li B, Ni JX
- 266** Sepsis one-hour bundle management combined with psychological intervention on negative emotion and sleep quality in patients with sepsis
Xia M, Dong GY, Zhu SC, Xing HM, Li LM

Contents

Monthly Volume 14 Number 2 February 19, 2024

- 276** Neuropathological characteristics of abnormal white matter functional signaling in adolescents with major depression

Huang XL, Gao J, Wang YM, Zhu F, Qin J, Yao QN, Zhang XB, Sun HY

Observational Study

- 287** Depression and anxiety among cancer patients visiting a tertiary care cancer hospital

Kaphle M, Bajracharya D, Regmi N, Aryal D, Karki R

- 296** Disparities in the impact of economic well-being on self-esteem in adulthood: Race and ethnicity

Lee J

Prospective Study

- 308** Risk factors for cognitive impairment in patients with chronic kidney disease

Wang XH, He Y, Zhou H, Xiao T, Du R, Zhang X

META-ANALYSIS

- 315** Alterations of sleep deprivation on brain function: A coordinate-based resting-state functional magnetic resonance imaging meta-analysis

Zhang Q, Hou YZ, Ding H, Shu YP, Li J, Chen XZ, Li JL, Lou Q, Wang DX

LETTER TO THE EDITOR

- 330** Using ChatGPT to promote college students' participation in physical activities and its effect on mental health

Zhang YF, Liu XQ

ABOUT COVER

Editorial Board Member of *World Journal of Psychiatry*, Hector Wing Hong Tsang, PhD, OTR, Chair Professor and Head, Department of Rehabilitation Sciences, Interim Director of Mental Health Research Centre, The Hong Kong Polytechnic University, Hong Kong 999077, China. hector.tsang@polyu.edu.hk

AIMS AND SCOPE

The primary aim of *World Journal of Psychiatry* (*WJP*, *World J Psychiatry*) is to provide scholars and readers from various fields of psychiatry with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJP mainly publishes articles reporting research results and findings obtained in the field of psychiatry and covering a wide range of topics including adolescent psychiatry, biological psychiatry, child psychiatry, community psychiatry, ethnopsychology, psychoanalysis, psychosomatic medicine, etc.

INDEXING/ABSTRACTING

The *WJP* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJP* as 3.1; IF without journal self cites: 2.9; 5-year IF: 4.2; Journal Citation Indicator: 0.52; Ranking: 91 among 155 journals in psychiatry; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Psychiatry

ISSN

ISSN 2220-3206 (online)

LAUNCH DATE

December 31, 2011

FREQUENCY

Monthly

EDITORS-IN-CHEF

Ting-Shao Zhu

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3206/editorialboard.htm>

PUBLICATION DATE

February 19, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Submit a Manuscript: <https://www.f6publishing.com>*World J Psychiatry* 2024 February 19; 14(2): 194-198

DOI: 10.5498/wjp.v14.i2.194

ISSN 2220-3206 (online)

EDITORIAL

Keep in mind sex differences when prescribing psychotropic drugs

Marianna Mazza, Domenico De Berardis, Giuseppe Marano

Specialty type: Psychiatry**Provenance and peer review:**

Invited article; Externally peer reviewed.

Peer-review model: Single blind**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Joseph MA, Oman; Seeman MV, Canada**Received:** October 8, 2023**Peer-review started:** October 8, 2023**First decision:** November 30, 2023**Revised:** December 2, 2023**Accepted:** January 2, 2024**Article in press:** January 2, 2024**Published online:** February 19, 2024**Marianna Mazza, Giuseppe Marano**, Department of Neurosciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy**Domenico De Berardis**, Mental Health, NHS, ASL 4 Teramo, Teramo 64100, Italy**Corresponding author:** Marianna Mazza, MD, PhD, Assistant Professor, Department of Neurosciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo A Gemelli 8, Rome 00168, Italy. mariannamazza@hotmail.com

Abstract

Women represent the majority of patients with psychiatric diagnoses and also the largest users of psychotropic drugs. There are inevitable differences in efficacy, side effects and long-term treatment response between men and women. Psychopharmacological research needs to develop adequately powered animal and human trials aimed to consider pharmacokinetics and pharmacodynamics of central nervous system drugs in both male and female subjects. Healthcare professionals have the responsibility to prescribe sex-specific psychopharmacotherapies with a priority to differentiate between men and women in order to minimize adverse drugs reactions, to maximize therapeutic effectiveness and to provide personalized management of care.

Key Words: Women; Psychopharmacology; Psychotropic drugs; Sex differences**©The Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: It has been largely demonstrated that women are the majority of patients with psychiatric diagnoses and also the largest users of psychotropic drugs. There are differences between men and women receiving psychotropic drugs, in terms of response, efficacy, side effects, long-term treatment outcome. There is still a lack of psychopharmacological research focusing on these differences in male and female patients. This editorial focuses on the important issue of deeply understanding the pharmacokinetics and pharmacodynamics of central nervous system drugs with a priority to differentiate between men and women in order to provide personalized management of care.

Citation: Mazza M, De Berardis D, Marano G. Keep in mind sex differences when prescribing psychotropic drugs. *World J Psychiatry* 2024; 14(2): 194-198
URL: <https://www.wjgnet.com/2220-3206/full/v14/i2/194.htm>
DOI: <https://dx.doi.org/10.5498/wjp.v14.i2.194>

INTRODUCTION

Notwithstanding both biological research and clinical experience have largely demonstrated that pathophysiological dissimilarities between men and women significantly influence the pharmacokinetics and pharmacodynamics of psychotropic drugs, most central nervous system drugs are prescribed to women and men at the same doses[1]. Sex differences in neural and behavioral outcomes have been described in the majority of neuroimaging studies evaluating the response to antidepressants, antipsychotics, sedative-hypnotics, stimulants and mood stabilizers[2]. Sex differences exist in every major part of the brain[3], hormones and neurosteroids affect the brains of men and women differentially and dissimilar biological mechanisms may underlie sex differences in responsiveness to stress[4].

Gender psychopharmacology is a complex field of study: Not only biological and physiological differences have a pivotal importance, but also all those factors that contribute to the formation of the individual, such as psychological behaviour, social role, cultural characteristics contribute significantly. Personalized medicine could become the future, designing suitable drugs or providing more appropriate doses, with different administration intervals. Men and women use drugs and other health interventions differently, for biological reasons, as they get sick differently (for example, men seem to have higher pain tolerance and more lethal conditions, whereas women have a stronger immune response but more disabling chronic conditions) and socio-cultural reasons, as they have different attitudes toward health and care[5]. Besides, men and women respond differently to pharmacotherapies, because the drugs are absorbed and eliminated differently or because there are differences in the sensitivity and distribution of the targets on which these substances act. Gender differences in drug response are based on pharmacokinetic and pharmacodynamic variations, such as bioavailability, volume of distribution and binding to plasma proteins. There are also differences in metabolism and drug excretion: Women produce less creatinine, have a lower glomerular filtrate volume than men, and there is a tendency for women to accumulate drugs. On average, men have larger body sizes that result in larger distribution volumes and faster total clearance of most medications in men compared to women. Greater body fat in women (until older ages) may increase distribution volumes for lipophilic drugs[6].

Over the course of life, women undergo several hormonal changes connected, for example, to the onset and end of the menstrual cycle as well as pregnancy and the post-partum period. Pregnancy and lactation modify all pharmacokinetic parameters, due to changes in the volume of distribution. Besides, the placenta is a drug-metabolizing organ and the enzymes in the placenta are different from those in the liver[5].

WOMEN AND PSYCHOTROPIC DRUGS: FUTURE PERSPECTIVES OF RESEARCH

Women represent the majority of patients with psychiatric diagnoses and also the largest users of psychotropic drugs, especially antidepressants[7,8]. More women than men take multiple medications, and are more vulnerable to a number of adverse drug reactions. The reasons for this increased risk include gender-related differences in pharmacokinetic, immunological and hormonal factors (Figure 1). Among these differences, variation in levels and changes in sex steroids that subsequently interact with neurotransmitters, lower lean body mass compared to men, reduced hepatic clearance, different activity of cytochrome P450 enzymes with consequent different rates of metabolism, as well as conjugation, absorption, protein binding and renal elimination should be considered[9]. Besides, important issues regard the increased risk of QT prolongation at electrocardiogram with certain drugs compared with men even at equivalent serum concentrations and specific cutaneous reactions due to possible gender differences in T cell activation and proliferation (Figure 2). The prevalence of side effects in women is moderated by readiness to report, pain threshold, nature of the side effect, adherence to prescription, therapeutic alliance, genetic differences. It can be argued how both sex-related than gender-related factors (lifestyle factors, communication styles, health information-seeking behaviour, differences in social roles, and medication prescribing and adherence) could also lead to gender-specific differences in the occurrence, perception and reporting of adverse drug reactions. For example, women and men may perceive symptoms differently; women seem to search more actively for health information than men; there are often differences in the dose of drugs or duration of therapies prescribed to women as compared to men[10].

There is an increase of the rates of individuals reporting the use of any psychiatric medications over the last few decade, and in particular rates of antidepressant, benzodiazepine and antipsychotic use seem to be higher in females[11]. Although these data witness the advancements of medicine and the improvement of the quality of life of psychiatric patients, the other side of the coin is represented by the inevitable consideration of differences in efficacy, side effects and long-term treatment response between males and females, probably related, almost in part, to sex differences in how these drugs act on the brain and are metabolized and excreted. In addition, reproductive-aged women have repetitive variations in sex hormones with each monthly cycle that influence the onset, chronicity, and outcome of a variety of psychiatric illnesses[12].




Figure 1 Gender differences in pharmacokinetics and pharmacodynamics.




Figure 2 Factors influencing gender-based drug response.

The complexity of women's hormonal physiology translates into mood instability related to the menstrual cycle, the manifold physiological changes of pregnancy, and, finally, the extremely complicated phase of menopause. Levels of sex hormones throughout the menstrual cycle are associated with the activation of specific hepatic enzymes and the rate of clearance of certain drugs, while the main differences between men and women in drug kinetics disappear at menopause due to the progressive decline in the production of estrogen and progesterone[7].

The specificity of psychopharmacological treatment in women arise from sex-related mechanisms of pharmacodynamics and pharmacokinetics up to peculiarities in terms of absorption, distribution, metabolism, and excretion. For example, in the prescription of antipsychotics, like olanzapine and clozapine, the effective dose for a woman might need to be lower than guidelines recommend for men on average (men with psychosis often require higher dosages of antipsychotic drugs related to their greater liver enzymatic clearance), while some antipsychotic side effects, weight gain for instance, are more worrisome for women than for men. After menopause, women need an increase in their antipsychotic dose, due to the decline of endogenous estrogen levels; other reproductive stages in women's lives require special prescribing considerations as well[13-15].

Notwithstanding the number of trials enrolling women has increased following the instructions of Food and Drug Administration, women are still less represented in clinical trials because both pharmacokinetics and pharmacodynamics of a drug can be influenced by menstrual cycle phases, hormonal fluctuations, use of oral contraceptives and hormonal therapy, and life events such as pregnancy and lactation.

Clinicians should always keep in mind sex differences when prescribing psychotropic drugs and there must be adequate academic and scientific information on the potential impact of sex-related factors that affect pharmacokinetics and pharmacodynamics processes. This topic results critical in order to ensure drug safety and efficacy for females and males, and for informing clinical product monographs and consumer information.

There is a need of adequately powered psychopharmacological researches aimed to consider both male and female subjects in animal and human studies. In addition, clinical trials should necessarily analyze sex-related differences in results. Evaluation of the effects of sex can help to explain seemingly contradictory findings of pharmacological studies. In future researches, it could be interesting to deepen sex-specific differences in response to antidepressant therapy[16], to compare the clinical trajectory of women and men with treatment-resistant depression treated with similar augmentation strategies[17], to test different psychotropic drugs aiming to individuate which may have a greater efficacy on women than men[18] or to better evaluate sex differences in studies examining the role of the glutamate system in psychiatric disease[19]. Not only women often use drugs differently and respond to drugs differently, but they can also have unique obstacles to effective treatment (for example not being able to find child care or being prescribed treatment that has not been adequately tested on women)[20]. Although men are more likely than women to use almost all types of illicit drugs, there is evidence that women may be more susceptible to craving and relapse[21], therefore, influencing psychopharmacological treatment in terms of comorbidity and compliance with therapy. It could be useful to identify more precisely which gender-related psychosocial factors, environmental factors (chemical pollutants, cigarette smoking or oral contraceptives, nutritional variables) and psychological factors, in terms of patients' beliefs, attitudes and expectations, that can affect the efficacy of a prescribed pharmacotherapy, and this issue results particularly applicable to centrally acting drugs.

CONCLUSION

Studying and recognizing differences between both sexes is the first step in ensuring equity and appropriateness of care. Sex is a key variable that cannot be neglected to optimize psychopharmacological treatment and to improve the efficacy and safety of drug use[22]. The development of sex-specific psychopharmacological research should aim to create a link between researchers and physicians for careful evaluation of biological, physiological, and pathological differences between men and women for the purpose of an increasing level of personalized medicine. On one hand, it is imperative to better identify the most urgent priorities and to increase awareness and knowledge about the mechanisms underlying the differences. On the other hand, it is crucial to stimulate the development of scientific and regulatory pathways that ensure that male and female populations are studied specifically and selectively.

Neuropsychopharmacology research should necessarily and primarily consider sex as a biological variable in order to reduce costs and improve benefits, reproducibility of results and rigor of methodology. Treatment guidelines should always take into account sex-related factors and their influence on pharmacokinetics and pharmacodynamics processes as well as the occurrence of adverse drug reactions and events. Healthcare professionals have a responsibility to understand the pharmacokinetics and pharmacodynamics of central nervous system drugs with a priority to differentiate between men and women in order to minimize the adverse drug reactions, to maximize the therapeutic effectiveness, to provide personalized management of care of patients and to contribute to the development of sex-specific psychopharmaceuticals.

FOOTNOTES

Author contributions: Mazza M, De Berardis D, and Marano G designed the research study and wrote the manuscript; and all authors have read and have approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/Licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Marianna Mazza 0000-0002-3007-8162; Domenico De Berardis 0000-0003-4415-5058; Giuseppe Marano 0000-0001-7058-4927.

S-Editor: Wang JJ

L-Editor: A

P-Editor: Chen YX

REFERENCES

- 1 **Romanescu M**, Buda V, Lombrea A, Andor M, Ledeti I, Suciu M, Danciu C, Dehelean CA, Dehelean L. Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review. *J Pers Med* 2022; **12** [PMID: 35743692 DOI: 10.3390/jpm12060907]
- 2 **Duffy KA**, Epperson CN. Evaluating the evidence for sex differences: a scoping review of human neuroimaging in psychopharmacology research. *Neuropsychopharmacology* 2022; **47**: 430-443 [PMID: 34732844 DOI: 10.1038/s41386-021-01162-8]
- 3 **Cahill L**. Why sex matters for neuroscience. *Nat Rev Neurosci* 2006; **7**: 477-484 [PMID: 16688123 DOI: 10.1038/nrn1909]
- 4 **Bolea-Alamanac B**, Bailey SJ, Lovick TA, Scheele D, Valentino R. Female psychopharmacology matters! Towards a sex-specific psychopharmacology. *J Psychopharmacol* 2018; **32**: 125-133 [PMID: 29405799 DOI: 10.1177/0269881117747578]
- 5 **Crimmins EM**, Shim H, Zhang YS, Kim JK. Differences between Men and Women in Mortality and the Health Dimensions of the Morbidity Process. *Clin Chem* 2019; **65**: 135-145 [PMID: 30478135 DOI: 10.1373/clinchem.2018.288332]
- 6 **Schwartz JB**. The influence of sex on pharmacokinetics. *Clin Pharmacokinet* 2003; **42**: 107-121 [PMID: 12537512 DOI: 10.2165/00003088-200342020-00001]
- 7 **Estancial Fernandes CS**, de Azevedo RCS, Goldbaum M, Barros MBA. Psychotropic use patterns: Are there differences between men and women? *PLoS One* 2018; **13**: e0207921 [PMID: 30475871 DOI: 10.1371/journal.pone.0207921]
- 8 **Boyd A**, Van de Velde S, Pivette M, Ten Have M, Florescu S, O'Neill S, Caldas-de-Almeida JM, Vilagut G, Haro JM, Alonso J, Kovess-Masfety V; EU-WMH investigators. Gender differences in psychotropic use across Europe: Results from a large cross-sectional, population-based study. *Eur Psychiatry* 2015; **30**: 778-788 [PMID: 26052073 DOI: 10.1016/j.eurpsy.2015.05.001]
- 9 **Rademaker M**. Do women have more adverse drug reactions? *Am J Clin Dermatol* 2001; **2**: 349-351 [PMID: 11770389 DOI: 10.2165/00128071-200102060-00001]
- 10 **de Vries ST**, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, van Puijenbroek EP. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. *Br J Clin Pharmacol* 2019; **85**: 1507-1515 [PMID: 30941789 DOI: 10.1111/bcpt.13923]
- 11 **Johansen ME**. Psychiatric Medication Users by Age and Sex in the United States, 1999-2018. *J Am Board Fam Med* 2021; **34**: 732-740 [PMID: 34312266 DOI: 10.3122/jabfm.2021.04.200596]
- 12 **Kornstein SG**, Clayton AH. Women's Mental Health. *Psychiatr Clin North Am* 2023; **46**: xiii-xiv [PMID: 37500256 DOI: 10.1016/j.psc.2023.04.016]
- 13 **Li R**, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? *J Transl Neurosci (Beijing)* 2016; **1**: 37-42 [PMID: 29152382]
- 14 **Seeman MV**. The Pharmacodynamics of Antipsychotic Drugs in Women and Men. *Front Psychiatry* 2021; **12**: 650904 [PMID: 33897500 DOI: 10.3389/fpsyg.2021.650904]
- 15 **Mazza M**, Caroppo E, De Berardis D, Marano G, Avallone C, Kotzalidis GD, Janiri D, Moccia L, Simonetti A, Conte E, Martinotti G, Janiri L, Sani G. Psychosis in Women: Time for Personalized Treatment. *J Pers Med* 2021; **11**: 1279 [PMID: 34945748 DOI: 10.3390/jpm11121279]
- 16 **Sramek JJ**, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. *Dialogues Clin Neurosci* 2016; **18**: 447-457 [PMID: 28179816 DOI: 10.31887/DCNS.2016.18.4/ncutler]
- 17 **Moderie C**, Nuñez N, Fielding A, Comai S, Gobbi G. Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression. *Int J Neuropsychopharmacol* 2022; **25**: 479-488 [PMID: 35167671 DOI: 10.1093/ijnp/pyac017]
- 18 **Ma L**, Xu Y, Wang G, Li R. What do we know about sex differences in depression: A review of animal models and potential mechanisms. *Prog Neuropsychopharmacol Biol Psychiatry* 2019; **89**: 48-56 [PMID: 30165122 DOI: 10.1016/j.pnpbp.2018.08.026]
- 19 **Wickens MM**, Bangasser DA, Briand LA. Sex Differences in Psychiatric Disease: A Focus on the Glutamate System. *Front Mol Neurosci* 2018; **11**: 197 [PMID: 29922129 DOI: 10.3389/fnmol.2018.00197]
- 20 **National Institute on Drug Abuse**. Sex and Gender Differences in Substance Use. [cited 4 September 2023]. Available from: <https://nida.nih.gov/publications/research-reports/substance-use-in-women/sex-gender-differences-in-substance-use>
- 21 **Kennedy AP**, Epstein DH, Phillips KA, Preston KL. Sex differences in cocaine/heroin users: drug-use triggers and craving in daily life. *Drug Alcohol Depend* 2013; **132**: 29-37 [PMID: 23357742 DOI: 10.1016/j.drugalcdep.2012.12.025]
- 22 **Allevato M**, Bancovsky J. Psychopharmacology and women. In: RennóJ, Valadares G, Cantilino A, Mendes-Ribeiro J, Rocha R, da Silva AG. Women's mental health: A clinical and evidence-based guide. Switzerland: Springer Nature, 2020: 227-239



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjnet.com>

